{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:16:29Z","timestamp":1790846189406,"version":"4.1.0"},"reference-count":30,"publisher":"EDP Sciences","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1051\/medsci\/20062211947","type":"journal-article","created":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T12:06:28Z","timestamp":1299326788000},"page":"947-952","source":"Crossref","is-referenced-by-count":14,"title":["Inhibiteurs de mTOR : Des antiprolif\u00e9ratifs pl\u00e9iotropiques"],"prefix":"10.1051","volume":"22","author":[{"given":"Nicolas","family":"Pallet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beaune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Thervet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Anglicheau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2006,11,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Heitman J, Movva NR, Hall MN,et al.Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.Science1991; 253 : 905\u20139.","DOI":"10.1126\/science.1715094"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Sabers CJ, Martin MM, Brunn GJ,et al.Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.J Biol Chem1995; 270 : 815\u2013223.","DOI":"10.1074\/jbc.270.2.815"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Tee AR, Blenis J. mTOR, translational control and human disease. SeminCell Dev Biol2005; 16 : 29\u201337.","DOI":"10.1016\/j.semcdb.2004.11.005"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Loewith R, Jacinto E, Wullschleger S,et al.Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth.Mol Cell2002; 10 : 457\u201368.6.","DOI":"10.1016\/S1097-2765(02)00636-6"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism.Cell2006; 124 :471\u201384.","DOI":"10.1016\/j.cell.2006.01.016"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Schmelzle T, Tobias MN. MTOR : a central controller of cell growth.Cell2000; 103 : 253\u201362.","DOI":"10.1016\/S0092-8674(00)00117-3"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Gangloff YG, Mueller M, Dann SG,et al.Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development.Mol Cell Biol2004; 21 : 9508\u201316.","DOI":"10.1128\/MCB.24.21.9508-9516.2004"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Ruvinsky I, Sharon N, Lerer T,et al.Meyuhas ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis.Genes Dev2005; 19 : 2199\u2013211.","DOI":"10.1101\/gad.351605"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Beretta L, Gingras AC, Svitkin YV,et al.Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation.EMBO J1996; 15 : 658\u20136413.","DOI":"10.1002\/j.1460-2075.1996.tb00398.x"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Harrington LS, Finlay GM, Lamb RFet al.Restraining PI3K : motor signalling goes back to the membrane.Trends Biochem Sci2005; 30 : 35\u20134.","DOI":"10.1016\/j.tibs.2004.11.003"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Inoki K, Corradetti MN, Guan KL,et al.Dysregulation of the TSC mTOR pathway in human disease.Nat Genet2005; 37 : 19\u201325.16.","DOI":"10.1038\/ng1494"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Kahan BD for the rapamune US study group. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection : a randomised multicentre study.Lancet2000; 356 : 194\u201320.","DOI":"10.1016\/S0140-6736(00)02480-6"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Cahill BC, Somerville KT, Crompton JA,et al.Early experience with sirolimus in lung transplant recipients with chronic allograft rejection.J Heart Lung Transplant2003; 22 : 169\u201376.","DOI":"10.1016\/S1053-2498(02)00550-8"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Eisen HJ, Tuzcu EM, Dorent R,et al.RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.N Engl J Med2003; 349 : 847\u201358.","DOI":"10.1056\/NEJMoa022171"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Moses JW, Leon MB, Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.N Engl J Med2003; 349 : 1315\u201323.","DOI":"10.1056\/NEJMoa035071"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Bjornsti MA, Houghton PJ. The TOR pathway : a target for cancer therapy.Nat RevCancer2004; 4 : 335\u201341.","DOI":"10.1038\/nrc1362"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Chan S. Targeting the mammalian target of rapamycin (mTOR) : a new approach to treating cancer.Br J Cancer2004; 91 : 1420\u20134.","DOI":"10.1038\/sj.bjc.6602162"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Chan S, Scheulen ME, Johnston S,et al.Phase II study of temsirolimus (CCI-779) in heavily pretreated patients with locally advanced or metastatic breast cancer.J Clin Oncol2005; 23 : 5314\u201349.","DOI":"10.1200\/JCO.2005.66.130"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Atkins MB, Hidalgo M, Stadler WM,et al.Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.J Clin Oncol2004; 22 : 909\u201318.","DOI":"10.1200\/JCO.2004.08.185"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Galanis E, Buckner JC, Maurer MJ,et al.Phase II trial of Temsirolimus (CCI-779) in recurrent glioblastoma multiforme : a North central cancer treatment group study.Clin Oncol2005; 10 : 5294\u20139.","DOI":"10.1200\/JCO.2005.23.622"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Panwalkar A, Verstovsek S, Gilles FJ. Mammalian target of rapamycin inhibition as therapy for hematological malignancies.Cancer2004; 100 : 657\u201366.","DOI":"10.1002\/cncr.20026"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"El-Hashemite N, Zhang H, Henske FD. Mutation in TSC-2 and actication of mammalian target of rapamycine signaling pathway in renal angiolipoma.Lancet2003; 361 : 1346\u20139.","DOI":"10.1016\/S0140-6736(03)13044-9"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Tao Y, Kim J, Schrier RW,et al.Rapamycine markedly slows disease progression in a rat model of polycystic kidney disease.J Am Soc Nephrol2005; 16 : 46\u201351.","DOI":"10.1681\/ASN.2004080660"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Podder H, Stepkowski SM, Napoli KL,et al.Pharmacokinetic interactions augment toxicities of sirolimus\/cyclosporine combination.J Am Soc Nephrol2001; 12 : 1059\u201366.","DOI":"10.1681\/ASN.V1251059"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Pallet N, Thervet E, Le Corre D,et al.SRL inhibits human epithelial cells proliferation: effect on cyclin D3 mRNA expression and stability.Kidney Int2005; 67 : 2422\u201330.","DOI":"10.1111\/j.1523-1755.2005.00350.x"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Letavernier E, Peraldi M, Pariente A,et al.Proteinuria following a switch from calcineurin inhibitors to sirolimus.Transplantation2005; 80 : 1198\u2013207.","DOI":"10.1097\/01.tp.0000185200.17589.74"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Sartelet H, Toupance O, Lorenzato M,et al.Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidney.Am J Transplant2005; 5 : 2441\u20135.","DOI":"10.1111\/j.1600-6143.2005.01047.x"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Bonegio RG, Fuhro R, Wang Z,et al.Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.J Am Soc Nephrol2005; 7 : 2063\u201372.","DOI":"10.1681\/ASN.2004030180"},{"key":"R29","unstructured":"Mahe E, Morelon E, Lechaton S,et al.Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy.Transplantation.2005; 27 : 476\u201382."},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Chueh SC, Kahan B. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.Transplantation2003; 27 : 375\u201380.","DOI":"10.1097\/01.TP.0000074310.40484.94"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/20062211947\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T21:11:35Z","timestamp":1637356295000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/20062211947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":30,"journal-issue":{"issue":"11"},"alternative-id":["medsci20062211p947"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/20062211947","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}